Lanadelumab to prevent acquired angioedema attacks
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests if lanadelumab can prevent swelling attacks in people with acquired angioedema (AAE). Acquired angioedema is a rare condition that causes sudden swelling in the skin and other body parts. This medicine is given as a long-term shot to lower the number of attacks you have.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acquired angioedema (AAE) with repeated swelling attacks, without hives
- You have had at least one attack per month in the past before starting tranexamic acid (TAA) treatment
- You have decreased C1 inhibitor (C1INH) levels, decreased C4 and C1q levels, and no family history of angioedema
- You have anti-C1INH antibodies or a condition called monoclonal gammopathy of unknown significance
- You do not have a history of severe allergic reaction to biologic medicines
- You are not pregnant or breastfeeding, and are not participating in other clinical trials
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood samples (and optional skin samples) from people with angioedema to learn more about the condition and find better ways to diagnose and treat it. If you join, you may help scientists understand angioedema better.
This trial tests an oral medication called deucrictibant to prevent and treat swelling attacks in people with hereditary angioedema. It may help reduce the number and severity of attacks.
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
This study tests an oral medication that can be taken daily to prevent angioedema attacks and as a rescue treatment when attacks occur. It may help reduce the frequency and severity of swelling episodes.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
Hear when a new Angioedema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.